

04/03/00

JC777 U.S. PTO

04-04-00

H Box Sea

Please type a plus sign (+) inside this box → ☐PTO/SB/05 (4/98)  
Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. **S0-3181-00-US**First Inventor or Application Identifier **Jacob S. Tou**Title **See 1 in Addendum**Express Mail Label No. **EJ482621526US****APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages **29**]  
(preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **15**]
4. Oath or Declaration [Total Pages **1**]
- a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 3 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY  
FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT  
IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

**ADDRESS TO:**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
- a. ☒ Computer Readable Copy
  - b. ☒ Paper Copy (identical to computer copy)
  - c. ☒ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of  
(when there is an assignee) ☐ Attorney
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 ☐ Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
13. ☐ \* Small Entity ☐ Statement filed in prior application  
Statement(s) ☐ Status still proper and desired  
(PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
15. ☐ Other: \_\_\_\_\_

**16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:**

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: \_\_\_\_\_  
Prior application information: Examiner \_\_\_\_\_ Group / Art Unit: \_\_\_\_\_

**For CONTINUATION or DIVISIONAL APPS only:** The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name	Verne A. Luckow				
	Patent Department Central				
Address	Monsanto/G. D. Searle & Co.				
	PO BOX 5110				
City	Chicago	State	IL	Zip Code	60680-5110
Country	USA	Telephone	636-737-6827	Fax	636-737-6972

Name (Print/Type)	Verne Luckow	Registration No. (Attorney/Agent)	45,950
Signature	<i>Verne A. Luckow</i>	Date	4-3-2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tou, Jacob S.; Taylor, Douglas W.

Application No.: UNKNOWN

Group No.: UNKNOWN

Filed: 04/03/2000

Examiner: UNKNOWN

For: METHOD OF REMOVING N-TERMINAL ALANINE RESIDUES FROM POLYPEPTIDES WITH AEROMONAS AMINOPEPTIDASE

**Box Patent Application**  
**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

EXPRESS MAIL CERTIFICATE

"Express Mail" label number EJ482621526US


Date of Deposit 04/03/2000

I hereby state that the following *attached* paper or fee

SPECIFICATION (pages 1-29)  
Drawings (Figures 1-15)  
Computer readable copy of Sequence Listing  
Paper copy of Sequence Listing  
Statement under 1.821 (f)  
Utility Application Transmittal  
Return Receipt Postcard  
Fee Transmittal

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. section 1.10, on the date indicated above and is addressed to the Box Patent Application Assistant Commissioner for Patents, Washington, D.C. 20231.

MARGIE PINNELL

  
Signature of person mailing paper or fee

[illegible]

- [illegible]

<b>METHOD OF REMOVING N-TERMINAL ALANINE RESIDUES FROM POLYPEPTIDES WITH AEROMONAS AMINOPEPTIDASE .....</b>	<b>1</b>
<b>Priority.....</b>	<b>1</b>
<b>Field of the invention .....</b>	<b>1</b>
<b>Background of the invention.....</b>	<b>1</b>
<b>Summary of the invention.....</b>	<b>6</b>
<b>Definitions.....</b>	<b>8</b>
<b>Brief description of the figures.....</b>	<b>9</b>
<i>Figure 1 - Structure of Ala-hGH and hGH.....</i>	<i>9</i>
<i>Figure 2 - Process for Production of hGH from Ala-hGH.....</i>	<i>9</i>
<i>Figure 3 - Kinetics of removal of Ala from Ala-hGH by AAP .....</i>	<i>9</i>
<i>Figure 4 - Enzymatic cleavage process options - Column mode .....</i>	<i>9</i>
<i>Figure 5 - Batch mode cleavage of Ala-hGH .....</i>	<i>9</i>
<i>Figure 6 - Recirculation mode cleavage of Ala-hGH.....</i>	<i>10</i>
<i>Figure 7 - Cleavage efficiency analyzed by HPLC.....</i>	<i>10</i>
<i>Figure 8 - Product comparison by RP-HPLC .....</i>	<i>10</i>
<i>Figure 9 - Products of Ala-hGH treated with AAP analyzed by tryptic mapping.....</i>	<i>10</i>
<i>Figure 10 - Quantitative analysis of residual Ala-hGH in hGH by tryptic digest.....</i>	<i>10</i>
<i>Figure 11 - Product comparison by tryptic mapping .....</i>	<i>10</i>
<i>Figure 12 - Residual levels of Ala-hGH in the final product by tryptic mapping.....</i>	<i>10</i>
<i>Figure 13 - Cleavage efficiency analyzed by ES/MS .....</i>	<i>11</i>
<i>Figure 14 - Product analysis by RP-HPLC, SE-HPLC, and ES/MS.....</i>	<i>11</i>
<i>Figure 15 - Product analyzed by N-terminal sequencing.....</i>	<i>11</i>
<b>Detailed description of the invention .....</b>	<b>12</b>
General methods .....	12
Reagents.....	12
Protein Purification .....	12
<i>Example 1: Preparation of Alanyl-human growth hormone (Ala-hGH).....</i>	<i>13</i>
<i>Example 2: In-vitro processing of Ala-human growth hormone (Ala-hGH) with Aeromonas aminopeptidase in free solution.....</i>	<i>13</i>
<i>Example 3: In-vitro processing of Ala-human growth hormone (Ala-hGH) using immobilized aminopeptidase.....</i>	<i>15</i>
Preparation of immobilized aminopeptidase .....	15
In-vitro cleavage of Ala-human growth hormone (hGH) .....	15
Batch mode: .....	15
Table 1: Effect of temperature on batch mode cleavage of Ala-hGH using immobilized AAP .....	16
Circulation mode: .....	16
Table 2: Circulation mode cleavage of Ala-hGH at 28°C .....	17
Table 3: Circulation mode cleavage of Ala-hGH at 20°C .....	17
Flow-through mode: .....	18
Table 4. Flow-through mode cleavage at 28°C .....	18
<i>Example 4: Comparison of steady-flow and continuous-flow cleavage processes.....</i>	<i>19</i>
Table 5: Effect of flow rate on activity.....	19
Table 6: Re-circulation at 28°C in phosphate buffer .....	19
Table 7: Effect of temperature and residence time on steady-flow cleavage process: .....	20
<i>Example 5: Enhancement of AAP alanyl-processing activity with copper.....</i>	<i>21</i>
Immobilized Cu-AAP from Zn-AAP Sepharose: .....	21
Table 8: Activity of metallo-modified AAP against Leu-pNA .....	21
<i>Example 6: Detailed structural analysis of the product produced by treatment of Ala-hGH with Aeromonas aminopeptidase .....</i>	<i>22</i>
Purification of Ala-hGH .....	22
Dissolution/Refold: .....	22
Acid precipitation: .....	22
Enzymatic cleavage:.....	23
Cation column:.....	23

Anion column:.....	23
Structural analysis of the cleavage products.....	23
Amino acid analysis: .....	24
RP-HPLC analysis:.....	24
Peptide mapping using trypsin: .....	24
Electrospray mass spectrometry (ES/MS): .....	25
N-terminal sequencing:.....	25
<i>Example 7: In-vitro processing of Alanyl Tissue Factor Pathway Inhibitor (Ala-TFPI) using amino peptidase:.....</i>	<i>26</i>
<b>CLAIMS .....</b>	<b>27</b>
<b>METHOD OF REMOVING N-TERMINAL ALANINE RESIDUES FROM POLYPEPTIDES WITH AEROMONAS AMINOPEPTIDASE .....</b>	<b>29</b>
Abstract.....	29
<b>FIGURES.....</b>	<b>1</b>
Figure 1 - Structure of Ala-hGH and hGH .....	1
Figure 2 - Process for Production of hGH from Ala-hGH.....	2
Figure 3 - Kinetics of removal of Ala from Ala-hGH by AAP .....	3
Figure 4 - Enzymatic cleavage process options - Column mode.....	4
Figure 5 - Batch mode cleavage of Ala-hGH .....	5
Figure 6 - Recirculation mode cleavage of Ala-hGH.....	6
Figure 7 - Cleavage efficiency analyzed by HPLC .....	7
Figure 8 - Product comparison by RP-HPLC.....	8
Figure 9 - Products of Ala-hGH treated with AAP analyzed by tryptic mapping .....	9
Figure 10 - Quantitative analysis of residual Ala-hGH in hGH by tryptic digest .....	10
Figure 11 - Product comparison by tryptic mapping .....	11
Figure 12 - Residual levels of Ala-hGH in the final product by tryptic mapping .....	12
Figure 13 - Cleavage efficiency analyzed by ES/MS.....	13
Figure 14 - Product analysis by RP-HPLC, SE-HPLC, and ES/MS .....	14
Figure 15 - Product analyzed by N-terminal sequencing .....	15
<b>SEQUENCE LISTING.....</b>	<b>16</b>

## Method of removing N-terminal alanine residues from polypeptides with *Aeromonas* aminopeptidase

### *Priority*

The present application claims priority under Title 35, United States Code,  
5 § 119 of United States Provisional Application Serial No. 60/132,062, filed April 30,  
1999.

### *Field of the invention*

This invention describes a method of removing N-terminal alanine residues  
from polypeptides, preferably recombinant proteins, using an aminopeptidase  
10 derived from the marine bacterium *Aeromonas proteolytica*. Accordingly,  
*Aeromonas* aminopeptidase (AAP; E.C. 3.4.11.10) can be used to remove N-  
terminal alanyl residues from derivatives of human somatotropin (hST, human  
growth hormone, or hGH), porcine somatotropin (pST), and bovine somatotropin  
(bST), for example, to yield proteins having their native amino acid sequences. The  
15 enzyme reactions can be carried out in free solution, or the AAP can be  
immobilized on a solid support, for reactions carried out *in vitro*. An efficient  
method for converting Ala-hGH to hGH, for example, comprises expression of Ala-  
hGH in *E. coli*, recovery of inclusion bodies, solubilization and refolding in  
detergent, detergent removal by ultrafiltration, selective precipitation, enzyme  
20 cleavage, followed by two column chromatography steps.

### *Background of the invention*

Recombinant proteins that mimic or have the same structure as native  
proteins are highly desired for use in therapeutic applications, as components in  
vaccines and diagnostic test kits, and as reagents for structure/function studies.  
25 Mammalian, bacterial, and insect cells are commonly used to express recombinant  
proteins for such applications. Bacterial expression systems, however, are often  
used when large quantities of protein are needed for experimental or clinical  
studies, and the protein is capable of being refolded to its proper conformation.  
Bacterial systems, in particular, offer significant cost advantages over other  
30 expression vector systems when eukaryotic post-translational modifications (e.g.,  
glycosylation) are not required, or desired, in the final protein product.

Recombinant proteins expressed in bacteria, such as *E. coli*, are often sequestered into insoluble inclusion bodies. Heterologous proteins harvested from inclusion bodies often retain an additional amino acid residue such as methionine at their amino terminus. This methionine residue (encoded by the ATG start codon) is often not present, however, on native or recombinant proteins harvested from eukaryotic host cells. The amino termini of many proteins made in the cytoplasm of *E. coli*, however, are processed by enzymes, such as methionine aminopeptidase (Ben Bassat et al., *J. Bacteriol.* **169**: 751-757, 1987), so that upon expression the methionine is ordinarily cleaved off the N-terminus.

The amino acid composition of protein termini are biased in many different manners (Berezovsky et al., *Protein Engineering* **12**(1): 23-30, 1999). Systematic examination of N-exopeptidase activities led to the discovery of the 'N-terminal' or 'N-end rule': the N-terminal (f)Met is cleaved if the next amino acid is Ala, Cys, Gly, Pro, Ser, Thr, or Val. If this next amino acid is Arg, Asp, Asn, Glu, Gln, Ile, Leu, Lys or Met, the initial (f)Met remains as the first amino acid of the mature protein. The radii of hydration of the amino acid side chains was proposed as physical basis for these observations (Bachmain et al., *Science*, **234**: 179-186, 1986; Varshavsky, *Cell*, **69**: 725-735, 1992). The half-life of a protein (from 3 min to 20 hours), is dramatically influenced by the chemical structure of the N-terminal amino acid (Stewart et al., *J. Biol. Chem.*, **270**: 25-28, 1995; Griegoryev et al., *J. Biol. Chem.*, **271**: 28521-28532, 1996). Site-directed mutagenesis was subsequently used to confirm the 'N-end rule' by monitoring the life-span of recombinant proteins containing altered N-terminal amino acid sequences (Varshavsky, *Proc. Natl. Acad. Sci. USA*, **93**: 12142-12149, 1996). A statistical analysis of the amino acid sequences at the amino termini of proteins suggested that Met and Ala residues are over-represented at the first position, whereas at positions +2 and +5, Thr is preferred (Berezovsky et al., *Protein Engineering* **12**(1): 23-30, 1999). C terminal biases, however, show a preference for charged amino acids and Cys residues (Berezovsky et al., *Protein Engineering*, **12**(1): 23-30, 1999).

Recombinant proteins that retain the N-terminal methionine, in some cases, have biological characteristics that differ from the native species lacking the N-terminal methionine. Human growth hormone that retains its N-terminal methionine (Met-hHG), for example, can promote the induction of undesirable antibodies, compared to hGH purified from natural sources or recombinant hGH that is prepared in such a way that has the same primary sequence as native hGH (lacking an N-terminal methionine). Low-cost methods of generating recombinant

proteins that mimic the structure of native proteins are often highly desired for therapeutic applications (Sandman et al., *Bio/Technology* 13:504-6 (1995)).

5 One method of preparing native proteins in bacteria is to express the desired protein as part of a larger fusion protein containing a recognition site for an endoprotease that specifically cleaves upstream from the start of the native amino acid sequences. The recognition and cleavage sites can be those recognized by native signal peptidases, which specifically clip the signal peptide of the N-terminal end of a protein targeted for delivery to a membrane or for secretion from the cell. In other cases, recognition and cleavage sites can be engineered into the  
10 gene encoding a fusion protein so that recombinant protein is susceptible to other non-native endoproteases *in vitro* or *in vivo*. The blood clotting factor Xa, collagenase, and the enzyme enterokinase, for example, can be used to release different fusion tags from a variety of proteins. Economic considerations, however, generally preclude use of endoproteases on a large scale for pharmaceutical use.

15 Another method of preparing native proteins in bacteria is to use the enzyme methionine aminopeptidase (MAP) to process the N-terminal methionine from *E. coli*-derived recombinant proteins. Met-hGH, for example, can be treated with MAP to generate hGH. United States Patents 4,870,017 and 5,013,662 describe the cloning, expression, and use of *E. coli* methionine aminopeptidase to  
20 remove Met from a variety of peptides and Met-IL-2. The ability to release amino acids from a variety of peptide substrates was analyzed, revealing that MAP cleaves only N-terminal methionine on peptides that are at least three amino acids long. The nature of amino acids in the second and third positions also appear to be significant. Methionine was released, for example, from Met-Ala-Met; Met-Gly-Met, Met-Ala-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Thr-Gln-Leu (SEQ ID NO: 1), and Met-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Gln-Cys (SEQ ID NO: 2), but not Met-Phe-Gly, Met-Leu-Phe, Met-Met-Met, among others. No amino acids were released  
25 from Leu-Ala-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Thr-Gln-Leu (SEQ ID NO: 3), Ala-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Thr-Gln-Leu (SEQ ID NO: 4), or Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Gln-Cys (SEQ ID NO: 5).  
30

WO 84/02351 discloses a process for preparing ripe (native) proteins such as human growth hormone or human proinsulin from fusion proteins using leucine aminopeptidase. A fusion protein having the amino acid sequence  $(Y_m \dots Y_2 Y_1) \text{-(Pro)}_p \text{-(X}_1 \text{X}_2 \dots \text{X}_n)$  in which the  $(Y_m \dots Y_2 Y_1) \text{-(Pro)}_p$  is the pro-sequence and the rest is  
35 the ripe protein, m is an integer greater than 2, Y is an arbitrary amino acid, p is 0, if  $X_1$  or  $X_2$  is Pro, and 1 if  $X_1$  or  $X_2$  is different from Pro, X is an arbitrary amino

acid, and  $n$  is an integer greater than or equal to 4, is converted by stepwise cleavage with aminopeptidase removing amino acids  $Y_m \dots Y_2$  if  $p = 1$  or  $X_1 = \text{Pro}$ , or the groups  $Y_m \dots Y_2 - Y_1$  if  $X_2 = \text{Pro}$  and then the two amino acids  $Y_1 - \text{Pro}$  if  $p=1$  are cleaved off enzymatically in one or two steps in a manner known per se, and similarly  $Y_1$  alone is cleaved off, if  $X_1 = \text{Pro}$ .

European Patent Application EP 0 204 527 A1 discloses a method of removing the N terminal methionine from proteins of the formula H-Met-X-Pro-Y-OH to yield a protein represented by the formula H-X-Pro-Y-OH, where X is an amino acid other than proline and Y is a peptide chain. Aminopeptidase M was preferred, but leucine aminopeptidase, aminopeptidase PO, or aminopeptidase P could also be used. The N-terminal methionine was removed from derivatives of human interleukin-2 and human growth hormone.

*Aeromonas* aminopeptidase (AAP), an exo-peptidase isolated from the marine bacterium *Aeromonas proteolytica*, can also be used to facilitate the release of N-terminal amino acids from peptides and proteins (Wilkes et al., *Eur. J. Biochem.* **34**(3), 459-66, 1973). The most favorable sequence is X-/-Y- whereas Y is a hydrophobic residue, preferably an aromatic amino acid, such as phenylalanine. Residues susceptible to hydrolysis include all hydrophobic, aromatic, and basic amino acids, plus proline. Aspartyl, glutamyl, and cysteic acid residues were not removed from the amino terminus of any substrate tested, even at high enzyme concentrations. Asparagine, glutamine, and aminoethylated cysteine, however, were released from oligopeptide substrates. Glycine was generally resistant to hydrolysis, but was slowly released from some substrates, depending on the adjacent residues. The activity of AAP on peptide substrates can also be enhanced by changing the counter metal ions, such as  $\text{Cu}^{2+}$  and  $\text{Ni}^{2+}$  for free enzyme AAP (Prescott et al., *Biochem. Biophys. Res. Comm.* **114**(2): 646-652, 1983). AAP is a 29.5 kDa metalloenzyme containing two disulfide bonds.

European patent EP 0191827 B1 and U.S. patent 5,763,215 describe the sequential removal of N-terminal amino acids from analogs of eukaryotic proteins, formed in a foreign host, by use of *Aeromonas* aminopeptidase. When 8 mg methionyl-human growth hormone (Met-hGH) (dissolved in 1 mL pH 9.5 10 mM Na borate buffer) was mixed with *Aeromonas* aminopeptidase (dissolved at 0.4725 mg/mL in pH 9.5 Tris buffer) at a ratio of 900 to 19 and incubated at 37 °C, methionine cleavage was complete in 15 min. Cleavage of the new N-terminal amino acid leucine, was slight after 22 h. The N-terminal methionine from Met-pST, Met-Interferon, Met-IGF-1, Met-interleukin-2 (Met-IL-2), and Met-

Apolipoprotein E were removed by AAP. An N-terminal alanine, however, was not removed from mature superoxide dismutase.

5 More complicated methods can also be used to generate recombinant proteins with a native amino terminus. United States Patent 5,783,413, for example, describes the simultaneous or sequential use of (a) one or more aminopeptidases, (b) glutamine cyclotransferase, and (c) pyroglutamine aminopeptidase to treat amino-terminally-extended proteins of the formula  $\text{NH}_2\text{-A-glutamine-Protein-COOH}$  to produce a desired native protein. The first aminopeptidase(s) (selected from the group consisting of dipeptidylaminopeptidase  
10 I, *Aeromonas* aminopeptidase, aminopeptidase P, and proline aminopeptidase), catalyze the removal of residues amino-terminal to the glutamine. The glutamine cyclotransferase catalyzes the conversion of the glutamine to pyroglutamine, and the pyroglutamine aminopeptidase catalyzes the removal of pyroglutamine to produce the desired protein product.

15 United States Patents 5,565,330 and 5,573,923 disclose methods of removing dipeptides from the amino-terminus of precursor polypeptides involving treatment of the precursor with dipetidylaminopeptidase (dDAP) from the slime mold *Dictostelium descoideum*, which has a mass of about 225 kDa and a pH optimum of about 3.5. Precursors of human insulin, analogues of human insulin,  
20 and human growth hormone containing dipeptide extensions were processed by dDAP when the dDAP was in free solution and when it was immobilized on a suitable solid support surface.

25 More efficient strategies to process amino acids from the amino terminus of recombinant proteins are desirable to reduce the cost of generating therapeutic proteins that mimic the structure of native proteins. Methods that increase the levels of expression or facilitate the downstream processing of recombinant proteins will also accelerate the selection and development of small chemical molecules and other protein-based molecules destined for large scale clinical trials.

### *Summary of the invention*

It is an object of the invention is to describe a method of removing an N-terminal alanyl group from a recombinant protein which comprises contacting said recombinant protein with *Aeromonas* aminopeptidase such that said N-terminal  
5 alanyl group is removed and recovering the resulting recombinant protein.

Preferably, the recombinant protein is of eukaryotic origin. Even more preferably, the recombinant protein is selected from the group consisting of human growth hormone (hGH), bovine somatotropin (bST), porcine somatotropin (pST), and human tissue factor pathway inhibitor (TFPI). Most preferably, the  
10 recombinant protein is hGH.

Preferably, the contacting process is carried out at a pH from about pH 7 to about pH 11. Even more preferably, the contacting process is carried out at a pH from about pH 8 to about pH 10. Most preferably, the contacting process is carried out at a pH of about pH 8.0 to about pH 9.5.

Preferably, the contacting process is carried out in the presence of a buffer selected from the group consisting of borate, CHES, sodium bicarbonate, sodium phosphate, and Tris-HCl. More preferably, the buffer is borate, phosphate, or Tris-HCl.  
15

Preferably, the contacting process can be carried out wherein the aminopeptidase is immobilized. Preferably, the aminopeptidase is immobilized on a chromatography resin, chromatography surface, or chromatography gel.  
20

Preferably, the recombinant protein is passed through a column containing the aminopeptidase immobilized on a chromatography resin.

Alternatively, the contacting process can be carried out wherein the aminopeptidase is not immobilized (e.g., in free solution).  
25

It is also conceivable that *Aeromonas* aminopeptidase may permit the processing of proteins containing two or more closely-spaced alanyl residues in the N-terminal regions of polypeptides. The aminopeptidase may proceed sequentially from the N-terminus of the polypeptide or perhaps recognize additional alanine residues within a short distance of exposed N-terminal polypeptide residues. Elucidation of a consensus sequence for the alanyl-specific recognition and cleavage sites can be evaluated on a variety of protein and peptide substrates.  
30

5       *Aeromonas* aminopeptidase may also facilitate the processing of non-alanyl residues in the N-terminal regions of proteins under the conditions disclosed in this application. Elucidation of a consensus sequence for the recognition and cleavage of these sites can be evaluated on a variety of protein and peptide substrates.

10       It is another object of the invention is to describe a method of removing amino-terminal amino acids from a precursor polypeptide of the formula X-Y-Pro-Z with *Aeromonas* aminopeptidase to yield a polypeptide of the formula Y-Pro-Z, wherein X is one or more amino acids except proline, Y is any amino acid except proline, and Z is one or more amino acids.

Preferably, X is alanine.

Preferably, Y is selected from the group consisting of phenylalanine, methionine, threonine, and aspartic acid. More preferably, Y is phenylalanine.

Most preferably, X is alanine and Y is phenylalanine.

15       Preferably, the precursor polypeptide is Ala-hGH.

### Definitions

The following is a list of abbreviations and the corresponding meanings as used interchangeably herein:

- g = gram(s)
- 5 HPLC = high performance liquid chromatography
- kb = kilobase(s)
- mb = megabase(s)
- mg = milligram(s)
- ml, mL = milliliter(s)
- 10 RP-HPLC = reverse phase high performance liquid chromatography
- ug, µg = microgram(s)
- ul, uL, µl, µL = microliter(s)

The following is a list of definitions of various terms and the corresponding meanings as used interchangeably herein:

- 15 The terms "aap" and "AAP" mean *Aeromonas* aminopeptidase.
- The terms "ap" and "AP" mean aminopeptidase.
- The term "amino acid(s)" means all naturally occurring L-amino acids, including norleucine, norvaline, homocysteine, and ornithine.
- The term "fusion molecule" means a protein-encoding molecule or fragment
- 20 thereof that upon expression, produces a fusion protein.
- The term "fusion protein" means a protein or fragment thereof that comprises one or more additional peptide regions not derived from that protein.
- The term "promoter" is used in an expansive sense to refer to the regulatory sequence(s) that control mRNA production.
- 25 The term "protein fragment" means a peptide or polypeptide molecule whose amino acid sequence comprises a subset of the amino acid sequence of that protein.
- The term "protein molecule/peptide molecule" means any molecule that comprises five or more amino acids.
- 30 The term "recombinant" means any agent (e.g., DNA, peptide, etc.), that is, or results from, however indirectly, human manipulation of a nucleic acid molecule.
- The term "specifically bind" means that the binding of an antibody or peptide is not competitively inhibited by the presence of non-related molecules.

The term “substantially-purified” means that one or more molecules that are or may be present in a naturally-occurring preparation containing the target molecule will have been removed or reduced in concentration.

### ***Brief description of the figures***

#### **Figure 1 - Structure of Ala-hGH and hGH**

Human growth hormone (right) is a single-chain polypeptide (22 kDa) with four cysteine residues involved in two disulfide bond linkages. The correct N-terminal sequence can be achieved by the *in-vitro* enzymatic cleavage of Ala-hGH (left) with *Aeromonas* aminopeptidase.

#### **Figure 2 - Process for Production of hGH from Ala-hGH**

A general process for the purification of hGH from Ala-hGH involves purification of Ala-hGH from bacterial inclusion bodies, refolding of Ala-hGH in detergent, detergent removal, acid precipitation, treatment with aminopeptidase, and purification of the native hGH by cation and anion exchange column chromatography.

#### **Figure 3 - Kinetics of removal of Ala from Ala-hGH by AAP**

The kinetics of removal of Ala from Ala-hGH by AAP are illustrated in Figure 3. Ala-hGH was present at 3 mg/ml and AAP at was present at 0.5, 1.0, 2.0, 3.0, and 4.0 units/ml in a total volume of 6 ml. The reactions were performed at room temperature and samples collected up through 25 hours and the products analyzed by ES/MS. Most of the reactions for the three highest concentrations of AAP were complete by 6 hours.

#### **Figure 4 - Enzymatic cleavage process options - Column mode**

A schematic comparison of steady-flow and continuous-flow cleavage process modes are illustrated.

#### **Figure 5 - Batch mode cleavage of Ala-hGH**

Figure 5 illustrates a time course of enhanced cleavage of Ala-hGH by Cu-AAP compared to Zn-AAP in batch mode.

**Figure 6 - Recirculation mode cleavage of Ala-hGH**

Figure 6 illustrates a time course of Ala-hGH by Cu-AAP compared to Zn-AAP carried out in column recirculation mode.

**Figure 7 - Cleavage efficiency analyzed by HPLC**

5                Figure 7 illustrates HPLC profiles of Ala-hGH before cleavage with AAP, incomplete cleavage, and after the reaction is complete.

**Figure 8 - Product comparison by RP-HPLC**

10                Figure 8 illustrates the HPLC profile of hGH prepared by treating Ala-hGH with AAP, and two commercial preparations of hGH (Humatrope and Zomacton).

**Figure 9 - Products of Ala-hGH treated with AAP analyzed by tryptic mapping**

15                Figures 9-12 illustrate typical tryptic map profiles. Figure 9 illustrates the profile tracings illustrating the difference in mobility of the Ala-T1 peptide compared to the T1 peptide.

**Figure 10 - Quantitative analysis of residual Ala-hGH in hGH by tryptic digest**

Figure 10 shows a vertically expanded profile tracing, illustrating the differences in peak areas under the elution positions for Ala-T1 and T1.

20                **Figure 11 - Product comparison by tryptic mapping**

Figure 11 illustrates the tryptic maps of hGH purified after treatment of Ala-hGH with AAP compared to tryptic maps of hGH from commercial sources (Humatrope and Zomacton).

25                **Figure 12 - Residual levels of Ala-hGH in the final product by tryptic mapping**

Figure 12 shows a vertically expanded profile tracing illustrating the presence or absence of Ala-T1 in a crude preparation of hGH, the final bulk preparation of hGH, and hGH from two commercial sources (Humatrope and Zomacton).

**Figure 13 - Cleavage efficiency analyzed by ES/MS**

Figure 13 illustrates ES/MS profiles of Ala-hGH before cleavage with AAP, incomplete cleavage, and after the reaction is complete. Figure 8 illustrates the HPLC profile of hGH prepared by treating Ala-hGH with AAP, and two commercial preparations of hGH (Humatrope and Zomacton).

**Figure 14 - Product analysis by RP-HPLC, SE-HPLC, and ES/MS**

Figure 14 illustrates a superimposed ES/MS profile of Ala-hGH and hGH (bottom panel) along with HPLC tracings of the final product resolved on RP-HPLC and SE-HPLC columns.

**Figure 15 - Product analyzed by N-terminal sequencing**

Figure 15 illustrates tracings of the products released after cycle 1 and cycle 2 from an automated protein sequencer. Phenylalanine (18.3 min) is the only significant residue detected after one cycle (left panel). Proline (14.2 min) is the only significant residue detected in cycle 2. The amount of alanine (\*) is negligible in both cycles, indicating lack of N-terminal alanine residues in the final purified product.

### ***Detailed description of the invention***

5 The following examples will illustrate the invention in greater detail, although it will be understood that the invention is not limited to these specific examples. Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

#### **General methods**

10 General methods of cloning, expressing, and characterizing proteins are found in T. Maniatis, et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982, and references cited therein, incorporated herein by reference; and in J. Sambrook, et al., *Molecular Cloning, A Laboratory Manual*, 2<sup>nd</sup> edition, Cold Spring Harbor Laboratory, 1989, and references cited therein, incorporated herein by reference. General and specific conditions and procedures  
15 for the construction, manipulation and isolation of antibodies are well known in the art (see, for example, Harlow and Lane, *In Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1988)).

#### ***Reagents***

20 *Aeromonas* aminopeptidase and all specialty chemicals, unless noted otherwise, were obtained from Sigma Chemical Company (St. Louis, MO).

Humatrope was obtained from Eli Lilly. Zomacton was obtained from Gentech.

#### ***Protein Purification***

25 Protein purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration, hydrophobic chromatography, or reversed phase HPLC. These and other protein purification methods are described in detail in *Methods in Enzymology*, Volume 182 "Guide to Protein Purification" edited by Murray Deutscher, Academic Press, San Diego, California, 1990. Folded proteins can also be affinity-purified using affinity  
30 reagents such as monoclonal antibodies or receptor subunits attached to a suitable matrix.

Purified proteins can be analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. Protein quantitation is accomplished by amino acid composition, RP-HPLC, and Bradford protein determination techniques. Tryptic peptide mapping, performed in conjunction with electrospray mass spectrometry, can also be used to confirm the identity of proteins.

#### **Example 1: Preparation of Alanyl-human growth hormone (Ala-hGH)**

Ala-hGH (Figure 1) was expressed in *E. coli* using mini-Mu-based chromosomal expression system (Weinberg et al., *Gene* **126**: 25-33, 1993; U.S. patents 5,395,763 and 5,514,483; U.S. patent application 09/044,369, filed March 19, 1998, each herein specifically incorporated by reference). Ala-hGH was expressed at levels of about 1.5 to about 2.0 g/liter.

Ala-hGH was purified, refolded, and processed to a purity of >90% based on analysis of Ala-hGH (by RP-HPLC) and total protein concentration (by absorbance at A<sub>280</sub>). Briefly, inclusion bodies were isolated and Ala-hGH was purified and refolded using methods described previously (WO 98/29433). Refolding was most commonly achieved with a >85% yield at pH 10 using as acyl-glutamate as a detergent. The detergent was then removed from the refold mixture by exhaustive ultrafiltration (10 TOVs) against pH 10 water. This was followed by an acid precipitation step to remove most of the recombinant *E. coli* proteins. The average recovery of Ala-hGH from this precipitation step was ~80-85%. This semi-purified Ala-hGH was diafiltered against the cleavage buffer (10 mM phosphate, pH 8.0) before being treated with the enzyme, preferably in an immobilized mode. After the enzymatic cleavage step, hGH was further purified by ion exchange chromatography to bulk powder. A general process outline is illustrated in Figure 2.

#### **Example 2: In-vitro processing of Ala-human growth hormone (Ala-hGH) with *Aeromonas* aminopeptidase in free solution**

Prior to the cleavage step, Ala-hGH was adjusted to 3 mg per ml concentration in 10 mM borate, pH 9.5. To this, *Aeromonas* aminopeptidase was added in 3 units per ml and the reaction was allowed to proceed for 24-36 hours at ambient temperature or at a shorter time at 37°C. The progress of the cleavage reaction can be monitored by RP-HPLC or by amino acid analysis of the release of alanine from Ala-hGH. At the end of reaction, the solution was quenched by adding 2% acetic acid (1:1.5 dilution *w/w*).

5

**Example 3: *In-vitro* processing of Ala-human growth hormone (Ala-hGH) using immobilized aminopeptidase**

*Preparation of immobilized aminopeptidase*

5            *Aeromonas* aminopeptidase (AAP) was coupled onto resins such as  
Sephacrose 4B resin via the cyanogen bromide (CNBr) chemistry. Commercial  
CNBr-activated Sepharose 4B resin was washed exhaustively with cold water and  
then suspended in 0.1 M sodium carbonate buffer, pH 8.5 or 10 mM phosphate, pH  
8. AAP was added (100 units per gram of resin) and the mixture was gently  
10           agitated at 4°C for overnight. After washing with water, the resin was capped with  
ethanolamine (0.5-1 M) at room temperature for two hours. Resin was then  
washed with water and equilibrated with the enzyme cleavage buffer, such as 10  
mM phosphate, pH 8. The activity of this immobilized enzyme was measured by  
the standard assay, suggested by Sigma, using L-leucine-p-nitroanilide as a  
substrate. The average activity was typically 10-20 units per ml of resin bed.

15           *In-vitro* cleavage of Ala-human growth hormone (hGH)

*Batch mode:*

             Immobilized aminopeptidase was suspended as 1:1 mix in borate or  
phosphate buffer. To a 7-ml tube containing 5 ml Ala-hGH in phosphate or borate  
buffer, one ml resin was added. This gave a total of 6 ml with 3 mg/ml protein  
20           concentration. The mixture was rocked for 10-24 hours at 20-40°C. At the end of  
reaction, resin was filtered off and the resulting solution was analyzed by RP-  
HPLC. The remaining of the solution was centrifuged using a CentriCon micro-  
filtration device. The filtrate was analyzed by the amino acid analyzer for the  
releasing of alanine. The retentate was exchanged 4-5 times with 2% acetic acid  
25           before being dried down to powder for mass spectrometry analysis.

             Table 1 illustrates the effect of temperature on batch mode cleavage of Ala-  
hGH using immobilized AAP. The reaction is accelerated at ambient  
temperatures, and essentially complete beyond 54 hours.

*Table 1: Effect of temperature on batch mode cleavage of Ala-hGH using immobilized AAP*

Temperature	Time, hrs	% cleavage
4-6°C	16	48
	54	65
	89	75
Ambient	16	82
	54	>97
	89	>97

*Circulation mode:*

5           Ala-hGH in 10 mM borate, pH 9.5 or 10 mM phosphate, pH 8.0 was  
circulated onto a Sepharose column that was previously immobilized with  
*Aeromonas* aminopeptidase. The volume of the reservoir is between 100 ml to 700  
ml depending on the concentration of the protein. Typically, Ala-hGH is in 5-10  
mg per ml. The flow rate is between 2-4 ml per minute. This was performed at  
10   20°C for about 24 hours. The reaction was monitored by RP-HPLC. Cleavage  
efficiency was confirmed by mass spectrometry and N-terminal sequencing.  
Finished product was then further purified by ion exchange chromatography.

15           Table 2 illustrates the effect of flow rate on cleavage of Ala-hGH using  
immobilized AAP at 28 °C in recirculation mode. Shorter residence times, were  
generally associated with higher levels of uncleaved substrate.

Table 2: Circulation mode cleavage of Ala-hGH at 28°C

Flow rate (ml/min)	Flow rate (ml/hr)	Residence time (hrs)	% Non-cleaved * Trypsin digest
0.119	7.14	7.14	0.92
0.167	10.03	5.08	1.18
0.262	15.72	3.24	2.11
0.400	24.00	2.13	(1.65)
0.573	34.38	1.48	2.26
0.867	52.02	0.98	2.17

\* The experiment was performed at 28°C in a column volume of 51 ml using 10 mM phosphate, pH 8 as buffer using Ala-hGH: 8 mg/ml (HPLC).

5

Table 3 illustrates the effect of flow rate on cleavage of Ala-hGH using immobilized AAP at 20°C in recirculation mode. Shorter residence times, directly correlated with higher levels of uncleaved substrate.

Table 3: Circulation mode cleavage of Ala-hGH at 20°C

Flow rate (ml/min)	Flow rate (ml/hr)	Residence time (hrs)	% Non-cleaved * Trypsin digest
0.117	7.02	7.26	1.34
0.164	9.84	5.18	2.12
0.255	15.27	3.34	3.83
0.404	24.21	2.11	4.54
0.567	34.87	1.46	5.20
0.849	50.94	1.00	14.99
1.23	73.64	0.69	21.27

The experiment was performed at 20°C with a column volume of 51 ml, in 10 mM phosphate buffer, pH 8 using Ala-hGH: 8 mg/ml (HPLC).

\* Approximately 1% are the cysteine adduct that co-eluted with the non-cleaved Ala-T1 peptide.

5

*Flow-through mode:*

Ala-hGH (8 mg/ml concentration) in 10 mM borate, pH 9.5 or 10 mM phosphate, pH 8.0 was introduced onto a Sepharose column (column volume is 50 ml) that was previously immobilized with *Aeromonas* aminopeptidase. The flow was adjusted to 15 ml per hour so the residence time to be around 3 hours. Cleavage efficiency was confirmed by RP-HPLC, tryptic digest, mass spectrometry or N-terminal sequencing. The eluent was collected and processed for downstream chromatographic purification.

Table 4 illustrates the effect of flow rate on cleavage of Ala-hGH using immobilized AAP at 28 °C in flow-through mode. Most of the Ala-hGH was processed by AAP under these conditions.

*Table 4. Flow-through mode cleavage at 28°C*

Flow rate (ml/hr)	Residence time (hrs)	% non-cleaved * (based on Trypsin digest)
7.14	7.14	<0.92
10.03	5.08	<1.18
15.72	3.24	<2.11
24	2.13	NA
34.4	1.48	<2.26
52.02	0.98	NA

\* All the tryptic data are based on the combination of uncleaved Ala-hGH and a process impurity. The real value of the uncleaved Ala-hGH is estimated about 50% of the reported values.

20

#### Example 4: Comparison of steady-flow and continuous-flow cleavage processes

Column mode cleavage can be done at a much lower flow rate *in one pass* as long as the overall residence time is met. Run #1 was a typical run in the re-circulating mode. Run #2 was operated at 1/10 of the flow rate of run #1. However, run #2 was performed at 175 min per pass as compared to 18 min per pass for run #1. The overall residence time for both runs is about the same, ~180 minutes. The two modes are illustrated in Figure 4.

Table 5: Effect of flow rate on activity

Run #	Column Volume, ml	Flow rate, ml/hr	Total passes	Residence time per pass	Residence time total contact time
1	57	192	10	18 min	180 min
2	57	19.8	1	175 min	175 min

Table 6 illustrates the effect of the number of passes on cleavage of Ala-hGH using immobilized AAP at 28°C in recirculation mode. Most of the Ala-hGH was processed by AAP under these conditions.

Table 6: Re-circulation at 28°C in phosphate buffer

Time, hrs	# passes	% cleavage	Analyzed by
2.92	1.06	>93	RP-HPLC
5.73	2.08	>96.1	Tryptic map
15.57	5.66	>98.6	Tryptic map
17.73	6.45	>98.6	Tryptic map
20.4	7.42	>98.6	Tryptic map
23.4	8.8	>98.8	Tryptic map

24.4	8.87	>98.8	Tryptic map
39.7	14.44	>99.2	Tryptic map

\* [Ala-hGH]= 9.2 mg/ml; 500 ml load

5 Table 7 illustrates the effect of temperature and residence time on cleavage of Ala-hGH. A ten degree difference in temperature appears to affect the cleavage efficiency. A longer residence time may be required if a higher % cleavage is needed.

*Table 7: Effect of temperature and residence time on steady-flow cleavage process:*

Run #	Temperature, °C	Flow rate, ml/hr	Residence time, min	% cleavage*
1A	20	0.28	182	>98.5
1B	30	0.28	182	>99.1
2A	20	0.51	100	>95.8
2B	30	0.51	100	>98.3

\* Cleavage products were analyzed by the peptide mapping method.

**Example 5: Enhancement of AAP alanyl-processing activity with copper**

5       The effects of substituting  $\text{Cu}^{2+}$  or  $\text{Ni}^{2+}$  for the native  $\text{Zn}^{2+}$  catalytic cofactor of AAP were examined in the immobilized system for *in vitro* processing of Ala-hGH. This Cu-AAP can be prepared either directly from the AAP purification process step or be converted to the copper species by replacing the zinc counter metals that is present as in the commercial material. The conversion can be done either as the free enzyme or as the immobilized form.

*Immobilized Cu-AAP from Zn-AAP Sepharose:*

10       Cu-AAP was immobilized as described above. Resin slurry (sample A, 20 ml with 10 ml resin bed volume) was placed in a 250-ml sinter-glass funnel and drawn to near dryness using by vacuum. To this, 20 ml of 50 mM Tricine/50 mM KCl, pH 7.5 and 20 mM 1,10 phenanthroline were added and mixed for 20 minutes. The solution was removed and placed in fresh buffer containing 1,10-phenanthroline and mixed for another 2 hours. The buffer was removed and the  
15       resin slurry was washed with water and HEPES buffer, pH 7.5. The resulting resin was divided into two tubes each with a total volume of 12 ml. To B, 0.2 mM  $\text{CuCl}_2$  in 50 mM HEPES, pH 7.5 was added, and to C, 0.2 mM  $\text{ZnCl}_2$  in 50 mM HEPES, pH 7.5 was added. Both tubes were rocked gently for 3 hours. The slurries were washed extensively with water and stored in the desired buffer, such  
20       as borate, pH 9.5.

*Table 8: Activity of metallo-modified AAP against Leu-pNA*

Samples	Metallo AAP	Activity unit/ml
		bed substrate: Leu-pNA
A (as is)	Zn-AAP	8.94
B	Zn-AAP	8.59
C	Cu-AAP	5.47

25       The rate of Ala-hGH cleavage by Cu-AAP and Zn-AAP was compared in both batch and recirculating column modes. In the batch cleavage trial, 0.5 ml of a 1:1 slurry of each resin (B or C) was added to 2.056 ml of 10 mM borate buffer, pH 9.5 prior to the addition of Ala-hGH to a final concentration of 0.8 mg/ml. The

reactions were followed over 24 hours by collection of samples that were quenched by filtering out the immobilized enzyme through a 0.45  $\mu$ m filter. The filtrate was then analyzed by RP-HPLC to determine the fraction of Ala-hGH that had been cleaved.

5           In the recirculating column cleavage trial, 1 cm x 5 cm columns were poured containing either the Cu-AAP resin (B) or the control AAP resin (B). These columns were equilibrated with 10 mM phosphate and 50 ml of 4.75 mg/ml Ala-hGH was recirculated through each of the columns at 2 CV per hour. Aliquots were collected and quenched at 3 hr, 6 hr, 18 hr and 28 hr for analysis as above.

10           Figure 5 illustrates a time course of enhanced cleavage of Ala-hGH by Cu-AAP compared to Zn-AAP in batch mode. Figure 6 illustrates a time course of Ala-hGH by Cu-AAP compared to Zn-AAP carried out in column recirculation mode.

15           Under all reaction conditions examined, Cu<sup>2+</sup>-substituted AAP was the most active against Ala-hGH (Figures 5 and 6), even though the Cu-AAP is less active in the hydrolysis of the chromogenic substrates Leu-p-nitroanilide (pNA) (Table 8).

#### **Example 6: Detailed structural analysis of the product produced by treatment of Ala-hGH with *Aeromonas* aminopeptidase**

##### *Purification of Ala-hGH*

20           *Dissolution / Refold:*

25           The inclusion body (IB) slurry was added to a pre-mixed solution containing 34.5 grams of sodium bicarbonate, 156 grams of amino-acid (e.g., sarcosine and/or glutamic acid) based detergent and 826 ml of water. The dissolved IB solution was held for 20 minutes at room temperature and cystine solution (100 mM, pH 10.0) was added. The solution was stirred for 15 hours at room temperature before cooling down to 4°C. The finished refold mixture was then concentrated to 4 liters, before being diafiltered against pH 10 water.

##### *Acid precipitation:*

30           The diafiltered solution was diluted with pH 10.0 water to an Ala-hGH concentration of ~2.5 mg/ml. A 2% acetic acid solution was added using a peristaltic pump until the pH reached ~5.6 at 4-6°C. The acidified solution was stirred for an additional 30 minutes. The solution was then centrifuged at 6000

RPM for 30 minutes using a Sorvall RC5C centrifuge at 4°C. The supernatant was decanted and was then diafiltered against 10 mM sodium phosphate, pH 8.0. The protein concentration was then adjusted to 8 mg/ml.

*Enzymatic cleavage:*

5            *Aeromonas* aminopeptidase was coupled onto resins such as Sepharose 4B resin via the cyanogen bromide chemistry (Hermanson, 1992). The activity of this immobilized enzyme was measured by the standard assay as suggested by Sigma using L-leucine-p-nitroanilide (Leu-pNA) as a substrate. Cold Ala-hGH solution (8 mg/ml) in 10 mM phosphate, pH 8.0 was passed through an immobilized enzyme  
10 column that was equipped with a water jacket and maintained at 25°C. The flow rate was adjusted to ~8 ml/hr to assure a sufficient contact time between Ala-hGH and the immobilized enzyme. The cleavage pool was then buffer exchanged against 3 M urea, 0.05 M acetic acid, pH 5.0 (buffer A) before loading onto the cation column.

15            *Cation column:*

The cation load was introduced onto a 2.2 x 20 cm Amicon column packed with CM Sepharose resin. The total column load was 2.0 g of Ala-hGH. After loading, the column was washed with 1 CV (column volume) of buffer A, then eluted with a salt gradient from 0-0.2 M NaCl over a total of 54 CVs. The flow rate  
20 was 4 CV/hour. Column eluent was collected in 0.2 CV fractions and the eluent was monitored with a Gilson holochrome detector at 280 nm. Fractions were analyzed by cation exchange HPLC, and fractions with >95% purity were pooled.

*Anion column:*

25            The cation pool was loaded onto a 1.6 x 20 cm Amicon column that was packed with Pharmacia Q-Sepharose resin. After loading, column was washed with one CV of Buffer A. A 40 CV linear gradient of 0-0.15 M NaCl in 0.05 M Tris-Cl pH 7.5 was done. The column eluent was collected as above. Fractions were analyzed by anion exchange HPLC and fractions with >98% purity were pooled.

*Structural analysis of the cleavage products*

30            The most convenient method for the analysis of a cleavage reaction is the RP-HPLC method. However, the only reliable quantitative analysis is the peptide digest method. In this method, the detection limit for Ala-T1 is 0.25%.

*Amino acid analysis:*

After the cleavage reaction, the solution was centrifuged using a Centricon with 10 kDa molecular weight cut-off membrane. The alanine concentration in the filtrate can be measured by an amino acid analyzer. The degree of cleavage can then be calculated by the amount of alanine released from the reaction. In addition, any other amino acid detected should be an indication of non-specific cleavage.

*RP-HPLC analysis:*

An isocratic method utilizing N-propanol (NPA)/0.25M phosphate pH 6.5 (26:74) as the mobile phase was used for analyzing Ala-hGH and hGH on a Vydac 214ATP54 column. The separation was carried out at 40°C. This method was used mainly in monitoring the formation of hGH via enzymatic cleavage of Ala-hGH. It also served as a secondary tool in deciding which fractions to collect from a cation exchange column.

Figures 7 and 8 illustrate typical HPLC profiles. Figure 7 illustrates HPLC profiles of Ala-hGH before cleavage with AAP, incomplete cleavage, and after the reaction is complete. Figure 8 illustrates the HPLC profile of hGH prepared by treating Ala-hGH with AAP, and two commercial preparations of hGH (Humatrope and Zomacton).

*Peptide mapping using trypsin:*

A solution of hGH was adjusted to pH 7.5 with 0.5 N NaOH. This solution was diluted with Tris base (50 mM, pH 7.5) so that the final concentration was 2 mg/ml. Then 15 mL of trypsin solution (1 mg/mL in 50 mM Tris base, pH 7.5) was added. The sample was mixed and incubated at 37 °C for 4 hrs, then quenched with 50 mL of HCl (0.5 M). An aliquot of the digested solution was injected on RP-HPLC and peptides were resolved by an acetonitrile gradient with 0.1% TFA.

This method provides information for the assessment of the primary and secondary structural integrity of hGH. Most importantly, this is the best method for analyzing trace level of un-cleaved Ala-hGH in the cleavage reaction and in the final product. The only difference between the tryptic digests of hGH and Ala-hGH is the N-terminal octa-peptide, T1 vs. Ala-T1. These two peptides are baseline resolved using an isocratic RP-HPLC method.

Ala-T1: AFPTIPLSR (SEQ ID NO: 7)

Figures 9-12 illustrate typical tryptic map profiles. Figure 9 illustrates the profile tracings illustrating the difference in mobility of the Ala-T1 peptide compared to the T1 peptide. Figure 10 shows a vertically expanded profile tracing, illustrating the differences in peak areas under the elution positions for Ala-T1 and T1. Figure 11 illustrates the tryptic maps of hGH purified after treatment of Ala-hGH with AAP compared to tryptic maps of hGH from commercial sources (Humatrope and Zomacton). Figure 12 shows a vertically expanded profile tracing illustrating the presence or absence of Ala-T1 in a crude preparation of hGH, the final bulk preparation of hGH, and hGH from two commercial sources (Humatrope and Zomacton).

*Electrospray mass spectrometry (ES/MS):*

Measurement is based on the peak intensity for hGH (22,125) and Ala-hGH (22,195). The presence of other peaks is indicative of non-specific enzymatic cleavage.

Figure 13 illustrates ES/MS profiles of Ala-hGH before cleavage with AAP, incomplete cleavage, and after the reaction is complete. Figure 8 illustrates the HPLC profile of hGH prepared by treating Ala-hGH with AAP, and two commercial preparations of hGH (Humatrope and Zomacton).

Figure 14 illustrates a superimposed ES/MS profile of Ala-hGH and hGH (bottom panel) along with HPLC tracings of the final product resolved on RP-HPLC and SE-HPLC columns.

*N-terminal sequencing:*

N-terminal protein sequencing was performed by standard methods. The relative amounts of Ala (present in Ala-hGH) and Phe (in hGH) as the N-terminal amino acid are indicative of the degree of cleavage. Internal cleavage can also be detected by N-terminal sequence analysis.

Figure 15 illustrates tracings of the products released after cycle 1 and cycle 2 from an automated protein sequencer. Phenylalanine (18.3 min) is the only significant residue detected after one cycle (left panel). Proline (14.2 min) is the only significant residue detected in cycle 2. The amount of alanine (\*) is negligible in both cycles, indicating lack of N-terminal alanine residues in the final purified product.

**Example 7: In-vitro processing of Alanyl Tissue Factor Pathway Inhibitor (Ala-TFPI) using amino peptidase:**

Ala-TFPI, isolated from *E. coli* (US 5,212,091), can be processed to TFPI using AAP in solution. Properly refolded Ala-TFPI is adjusted to 0.5-3 mg per ml concentration in 10 mM phosphate, pH 8.0 or 10 mM borate, pH 9.5. To this, *Aeromonas* aminopeptidase is added to a concentration of 3 units per ml and the reaction is allowed to proceed for 24-36 hours at ambient temperature or for a shorter time at 37°C. The progress of the cleavage reaction can be monitored by HPLC method or by amino acid analysis of the release of alanine from Ala-TFPI. At the end of reaction, the solution is quenched by adding 2% acetic acid (1:1.5 dilution *w/w*). The degree of cleavage is determined by HPLC analysis of the tryptic peptide fragments and by ES/MS of the isolated product.

Ala-TFPI can also be processed to TFPI using an immobilized AAP as described above. The degree of cleavage is determined by HPLC analysis of the tryptic peptide fragments and by ES/MS of the isolated product.

All references, patents, or patent applications cited herein are incorporated by reference in their entirety, as if written herein.

## Claims

1. A method of removing an N-terminal alanyl group from a recombinant protein which comprises contacting said recombinant protein with *Aeromonas* aminopeptidase such that said N-terminal alanyl group is removed and recovering the resulting recombinant protein.  
5
2. A method of claim 1 wherein said recombinant protein is of eukaryotic origin.
3. A method of claim 2, wherein said recombinant protein is selected from the group consisting of human growth hormone (HGH), bovine somatotropin (bST), porcine somatotropin (pST), and human tissue factor pathway inhibitor (TFPI).  
10
4. A method of claim 1, wherein said contacting is carried out at a pH from about pH 7 to about pH 11.
5. A method of claim 4, wherein said contacting is carried out at a pH from about pH 8 to about pH 10.  
15
6. A method of claim 5, wherein said contacting is carried out at a pH of about pH 8.0 to about pH 9.5.
7. A method of claim 1, wherein said contacting is carried out in the presence of a buffer selected from the group consisting of borate, CHES, sodium bicarbonate, sodium phosphate, and Tris-HCl.  
20
8. A method of claim 7, wherein said buffer is borate.
9. A method of claim 7, wherein said buffer is sodium phosphate.
10. A method of claim 7, wherein said buffer is Tris-HCl.  
25
11. A method of claim 1, wherein said aminopeptidase is immobilized.
12. A method of claim 11, wherein said aminopeptidase is immobilized on a chromatography resin, chromatography surface, or chromatography gel.

13. A method of claim 12 wherein said recombinant protein is passed through a column containing said aminopeptidase immobilized on a chromatography resin.
- 5 14. A method of claim 1, wherein said aminopeptidase is not immobilized (carried out in free solution).
15. A recombinant protein lacking an N-terminal alanine prepared by the method of claim 1.
- 10 16. A method of removing amino-terminal amino acids from a precursor polypeptide of the formula X-Y-Pro-Z with *Aeromonas* aminopeptidase to yield a polypeptide of the formula Y-Pro-Z, wherein X is one or more amino acids except proline, Y is any amino acid except proline, and Z is one or more amino acids.
17. The method of claim 16 wherein X is alanine.
- 15 18. The method of claim 16 wherein Y is selected from the group consisting of phenylalanine, methionine, threonine, and aspartic acid.
19. The method of claim 18, wherein Y is phenylalanine.
- 20 20. The method of claim 16, wherein X is alanine and Y is phenylalanine.
21. The method of claim 19 or claim 20, wherein the precursor polypeptide is Ala-hGH.

## Method of removing N-terminal alanine residues from polypeptides with *Aeromonas* aminopeptidase


### *Abstract*

This invention describes a method of removing N-terminal alanine residues  
5 from polypeptides, preferably recombinant proteins, using an aminopeptidase  
derived from the marine bacterium *Aeromonas proteolytica*. Accordingly,  
*Aeromonas* aminopeptidase (AAP; E.C. 3.4.11.10) can be used to remove N-  
terminal alanyl residues from derivatives of human somatotropin (hST, human  
10 growth hormone, or hGH), porcine somatotropin (pST), and bovine somatotropin  
(bST), for example, to yield proteins having their native amino acid sequences. The  
enzyme reactions can be carried out in free solution, or the AAP can be  
immobilized on a solid support, for reactions carried out *in vitro*. An efficient  
method for converting Ala-hGH to hGH, for example, comprises expression of Ala-  
hGH in *E. coli*, recovery of inclusion bodies, solubilization and refolding in  
15 detergent, detergent removal by ultrafiltration, selective precipitation, enzyme  
cleavage, followed by two column chromatography steps.

# FIGURES

*Figure 1 - Structure of Ala-hGH and hGH*


**CORRECT HUMAN GROWTH HORMONE N-TERMINAL  
SEQUENCE CAN BE ACHIEVED BY THE *IN-VITRO* ENZYMATIC  
CLEAVAGE OF ALA-HUMAN GROWTH HORMONE**



**Figure 2 - Process for Production of hGH from Ala-hGH**


Process Outline	Efficiency
Refold in Detergent	88%
↓	
Detergent Removal	>95%
↓	
Acid Precipitation	
↓	
Enzymatic Cleavage	>95%
↓	
Cation Exchange	67%
↓	
Anion Exchange	85%
↓	
Structural Analysis	

**Figure 3 - Kinetics of removal of Ala from Ala-hGH by AAP**



Studies of enzymatic removal of alanine from Ala-hGH: [Ala-hGH] 3 mg/ml; [AAP] 0.5, 1.0, 2.0, 3.0, and 4.0 units/ml; volume 6 ml. Cleavage efficiencies were determined by ES/MS. All reactions were performed at room temperature.


**Figure 4 - Enzymatic cleavage process options - Column mode**




**Re-circulation mode**  
192 ml/hr; 10 passes/24 hr  
Residence time= 180 min

**Flow-through mode**  
19.8 ml/hr; 1 pass  
Residence time= 175 min


**Figure 5 - Batch mode cleavage of Ala-hGH**




**Figure 6 - Recirculation mode cleavage of Ala-hGH**




**Figure 7 - Cleavage efficiency analyzed by HPLC**



**Figure 8 - Product comparison by RP-HPLC**




**Figure 9 - Products of Ala-hGH treated with AAP analyzed by tryptic mapping**



**Ala-T1: N-terminal peptide from Ala-hGH (top) (AFPTIPLSR)**


**T1: N-terminal peptide from hGH (bottom) ( FPTIPLSR)**

**Figure 10 - Quantitative analysis of residual Ala-hGH in hGH by tryptic digest**




**Baseline resolution of Ala-T1 and T1 peptides allows quantification of residual uncleaved Ala-hGH.**


**Figure 11 - Product comparison by tryptic mapping**



**Figure 12 - Residual levels of Ala-hGH in the final product by tryptic mapping**



**Figure 13 - Cleavage efficiency analyzed by ES/MS**



W D 63839904 C  
A 1a 3, G H  
E r cleavage


6383991261  
Incomplete cleavage

W D 6380141E9fin  
After cleavage  
h G H

**Figure 14 - Product analysis by RP-HPLC, SE-HPLC, and ES/MS**


### PRODUCT ANALYSIS

**Top:** RP-HPLC (Vydac C18) using 65-85%/20 min acetonitrile gradient in 1% TFA  
**Center:** SE-HPLC (BioRad Bio-Sil SEC 250) using 60% acetonitrile/80 mM TFA isocratic  
**Bottom:** ES/MS: Ala-hGH (22,198); hGH (22,125)



**Figure 15 - Product analyzed by N-terminal sequencing**

***In cycle 1 (left), Phe (18.3 min) is the only significant residue detected; Proline (14.2 min) is the expected residue for cycle 2 (right). The amount of alanine (\*, is negligible in both cycles indicating no Ala-hGH in the product.***



# Sequence Listing

## SEQUENCE LISTING

<110> Tou, Jacob

Taylor, Douglas

<120> Method of removing N-terminal alanine

residues from polypeptides with Aeromonas aminopeptidase

<130> S03108-00-US

<150> 60/132,062

<151> 1999-04-30

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide to test substrate specificity of  
E. coli methionine aminopeptidase

<400> 1

Met Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu

1

5

10

<210> 2

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide to test substrate specificity of

E. coli methionine aminopeptidase

<400> 2

Met Pro Thr Ser Ser Ser Thr Lys Lys Gln Cys

1 5 10

<210> 3

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide to test substrate specificity of  
E. coli methionine aminopeptidase

<400> 3

Leu Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu

1 5 10

<210> 4

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide to test substrate specificity of  
E. coli methionine aminopeptidase

<400> 4

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu

1 5 10

<210> 5

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide to test substrate specificity of  
E. coli methionine aminopeptidase

<400> 5

Pro Thr Ser Ser Ser Thr Lys Lys Gln Cys

1 5 10

<210> 6

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> T1 is the N-terminal tryptic peptide of native  
human hGH

<400> 6

Phe Pro Thr Ile Pro Leu Ser Arg

1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Ala-T1 is the N-terminal tryptic peptide of  
Ala-hGH

<400> 7

Ala Phe Pro Thr Ile Pro Leu Ser Arg

1 5